Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: An analysis of the PROVE-IT TIMI-22 trial

Journal of the American College of Cardiology

Volumn 45, Issue 10, 2005, Pages 1644-1648

  Ridker, Paul M ^a   Morrow, David A ^a   Rose, Lynda M ^a   Rifai, Nader ^a   Cannon, Christopher P ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

AGE DISTRIBUTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION RISK; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEX RATIO; SMOKING; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY RESTENOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; PYRROLES; RECURRENCE; STATISTICS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 18944371407     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.02.080     Document Type: Article

References (14)

1. S.M. Grundy, J.I. Cleeman, C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
2. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, E. Braunwald Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators Circulation 100 1999 230 235
3. M.A. Albert, E. Danielson, N. Rifai, P.M. Ridker Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
4. P.M. Ridker, N. Rifai, M. Clearfield Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965
5. I. Jialal, D. Stein, D. Balis Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 2001 1933 1935
6. P.M. Ridker, N. Rifai, M.A. Pfeffer Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol And Recurrent Events (CARE) Investigators Circulation 98 1998 839 844
7. P.M. Ridker, C.P. Cannon, D. Morrow PROVE-IT TIMI-22 Investigators C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
8. C.P. Cannon, E. Braunwald, C.H. McCabe PROVE-IT TIMI-22 Investigators Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
9. R.V. Milani, C.J. Lavie, M.R. Mehra Reduction in C-reactive protein through cardiac rehabilitation and exercise training J Am Coll Cardiol 43 2004 1056 1061
10. J.A. de Lemos, M.A. Blazing, S.D. Wiviott A to Z Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial JAMA 292 2004 1307 1316
11. C.M. Ballantyne, J. Houri, A. Notarbartolo Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia a prospective, randomized, double-blind trial Circulation 107 2003 2409 2415
12. J.P. Despres, I. Lemieux, A. Pascot Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome Arterioscler Thromb Vasc Biol 23 2003 702 703
13. S.M. Haffner, A.S. Greenberg, W.M. Weston Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 106 2002 679 684
14. P.M. Ridker Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein rationale and design of the JUPITER trial Circulation 108 2003 2292 2297